Suppr超能文献

免疫抑制宿主中的非结核分枝杆菌感染

Nontuberculous mycobacteria infections in immunosuppressed hosts.

作者信息

Henkle Emily, Winthrop Kevin L

机构信息

HIV, STD, and TB Section, Public Health Division, Oregon Health Authority, 800 NE Oregon Street, Suite 1105, Portland, OR 97232, USA.

Division of Infectious Diseases, Oregon Health and Science University, 3375 Southwest Terwilliger Boulevard, Mailstop CEI, Portland, OR 97239, USA; Division of Public Health and Preventative Medicine, Oregon Health and Science University, 3375 Southwest Terwilliger Boulevard, Mailstop CEI, Portland, OR 97239, USA.

出版信息

Clin Chest Med. 2015 Mar;36(1):91-9. doi: 10.1016/j.ccm.2014.11.002. Epub 2014 Dec 23.

Abstract

Diseases and therapies that reduce cell-mediated immunity increase the risk of nontuberculous mycobacterial (NTM) disease. Extrapulmonary NTM disease, including disseminated, skin, and catheter-related disease, is more common in immunosuppressed than immunocompetent patients. Mycobacterium avium complex remains the most common cause of NTM infection, but rapid growers including Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum play an important role in skin and catheter-related infections. With the exception of antibiotic prophylaxis for AIDS patients, the prevention of NTM remains difficult. Management is complicated, involving restoration of immune function and removal of catheters in addition to treatment with species-specific antibiotics per current guidelines.

摘要

降低细胞介导免疫的疾病和疗法会增加非结核分枝杆菌(NTM)病的风险。肺外NTM病,包括播散性、皮肤和导管相关疾病,在免疫抑制患者中比免疫功能正常的患者更常见。鸟分枝杆菌复合体仍然是NTM感染最常见的原因,但快速生长菌,包括脓肿分枝杆菌、龟分枝杆菌和偶然分枝杆菌,在皮肤和导管相关感染中起重要作用。除了对艾滋病患者进行抗生素预防外,NTM的预防仍然困难。管理很复杂,除了按照现行指南用针对特定菌种的抗生素治疗外,还涉及恢复免疫功能和拔除导管。

相似文献

1
Nontuberculous mycobacteria infections in immunosuppressed hosts.
Clin Chest Med. 2015 Mar;36(1):91-9. doi: 10.1016/j.ccm.2014.11.002. Epub 2014 Dec 23.
2
The treatment of rapidly growing mycobacterial infections.
Clin Chest Med. 2015 Mar;36(1):67-78. doi: 10.1016/j.ccm.2014.10.004. Epub 2014 Nov 5.
3
Treatment of slowly growing mycobacteria.
Clin Chest Med. 2015 Mar;36(1):79-90. doi: 10.1016/j.ccm.2014.10.005. Epub 2014 Nov 6.
5
Antibiotic treatment for nontuberculous mycobacterial lung disease.
Expert Rev Respir Med. 2016;10(5):557-68. doi: 10.1586/17476348.2016.1165611. Epub 2016 Mar 30.
7
Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches.
Expert Rev Respir Med. 2019 Sep;13(9):851-861. doi: 10.1080/17476348.2019.1638765. Epub 2019 Jul 8.
8
Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria.
Drug Resist Updat. 2012 Jun;15(3):149-61. doi: 10.1016/j.drup.2012.04.001. Epub 2012 Apr 21.
9
Macrophage Signaling Pathways in Pulmonary Nontuberculous Mycobacteria Infections.
Am J Respir Cell Mol Biol. 2020 Aug;63(2):144-151. doi: 10.1165/rcmb.2019-0241TR.

引用本文的文献

1
Multiple concurrent opportunistic infections in patient with myasthenia gravis: A case report.
Virulence. 2025 Dec;16(1):2545570. doi: 10.1080/21505594.2025.2545570. Epub 2025 Aug 28.
2
Analysis of nontuberculous mycobacterial infections in Saudi children from a tertiary care hospital perspective.
J Clin Tuberc Other Mycobact Dis. 2025 Jul 26;41:100554. doi: 10.1016/j.jctube.2025.100554. eCollection 2025 Dec.
3
Identification of a Drug Candidate against Using Pandemic Response Box.
J Microbiol Biotechnol. 2025 Aug 18;35:e2506006. doi: 10.4014/jmb.2506.06006.
4
Therapeutic Management Strategies Among Immunocompetent Infants with Nontuberculous Mycobacterial Pulmonary Infection.
Pediatric Health Med Ther. 2025 Jul 16;16:171-182. doi: 10.2147/PHMT.S513904. eCollection 2025.
5
Phenotyping Nontuberculous Mycobacterial Lung Disease: Comparative Analysis of Clinical and Imaging Features in a TB-Endemic Setting.
Infect Drug Resist. 2025 Jul 14;18:3527-3534. doi: 10.2147/IDR.S529466. eCollection 2025.
6
A Case of Delayed Refractory Abdominal Wall Abscess in a Kidney Transplant Recipient.
IJU Case Rep. 2025 May 9;8(4):369-372. doi: 10.1002/iju5.70042. eCollection 2025 Jul.
8
Pathogenicity and virulence of .
Virulence. 2025 Dec;16(1):2508813. doi: 10.1080/21505594.2025.2508813. Epub 2025 May 26.
9
Cochlear Implant Complicated by Nontuberculous Mycobacteria Infection: Report and Literature Review.
Case Rep Otolaryngol. 2025 Apr 30;2025:5973005. doi: 10.1155/crot/5973005. eCollection 2025.

本文引用的文献

1
Population-based Incidence of Pulmonary Nontuberculous Mycobacterial Disease in Oregon 2007 to 2012.
Ann Am Thorac Soc. 2015 May;12(5):642-7. doi: 10.1513/AnnalsATS.201412-559OC.
2
Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy.
Eur Respir J. 2014 Nov;44(5):1289-95. doi: 10.1183/09031936.00063514. Epub 2014 Aug 7.
4
Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: a population-based comparative study.
PLoS One. 2014 Mar 14;9(3):e91879. doi: 10.1371/journal.pone.0091879. eCollection 2014.
6
Mycobacterium haemophilum as the Initial Presentation of a B-Cell Lymphoma in a Liver Transplant Patient.
Case Rep Rheumatol. 2014;2014:742978. doi: 10.1155/2014/742978. Epub 2014 Jan 12.
7
Recurrent Mycobacterium haemophilum in a renal transplant recipient.
Nephrology (Carlton). 2014 Apr;19 Suppl 1:14-7. doi: 10.1111/nep.12193.
8
Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study.
Transpl Infect Dis. 2014 Feb;16(1):76-83. doi: 10.1111/tid.12170. Epub 2013 Dec 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验